Our ANS/inflammation-induced obesidome corroborates previous findings, yielding to future drug treatment focused on FOX1 and adrenergic regulation and revealing the beta-adrenergic receptor’s key role, whilst the stress-induced network evidences the role of asprosin and kisspeptin as drug candidates for obesity. Here, FBN1 is linked to obesity disorder.